Skip to content

Prime Medicine PRME Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Eli Lilly logo
Eli LillyLLY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
Beam Therapeutics logo
Beam TherapeuticsBEAM
Regenxbio logo
RegenxbioRGNX
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's software and technology licenses, net?
Prime Medicine (PRME) reported software and technology licenses, net of $1M in Q1 2026.
What is the long-term trend for Prime Medicine's software and technology licenses, net?
Over 4 years (2021 to 2025), Prime Medicine's software and technology licenses, net has grown at a -20.3% compound annual growth rate (CAGR), from $2.47M to $1M.